Tenet Healthcare Corp (THC) · Oct 29, 2026 · Earnings

Tenet earnings beat as EBITDA outlook jumps—but $147M was timing

Beat — Adjusted EPS $6.64 vs ~$4.68 consensus; revenue $5.631B vs ~$5.49B

Tenet’s Q3 earnings beat consensus and the company raised 2026 EBITDA and free-cash-flow guidance, though transition timing inflated the quarter.

Tenet is executing a two-part healthcare strategy: expanding its higher-margin ambulatory surgery platform while improving hospital utilization and cost control. The quarter advances that story, but the headline result includes a sizable revenue-cycle transition timing benefit.

The quarter cleared a high earnings bar. Adjusted diluted EPS was $6.64 versus about $4.68 consensus, while net operating revenue was $5.631 billion versus roughly $5.49 billion expected. That is a clear beat, not merely a favorable comparison with last year. Q3 adjusted EBITDA reached $1.355 billion, up 23.3% year over year, and the company raised full-year adjusted EBITDA guidance by $195 million at the midpoint.

Q3 2026Q3 2025Consensus
Adjusted diluted EPS (Financial Highlights)$6.64$3.70~$4.68
Net operating revenues (Financial Highlights)$5.631B$5.289B~$5.49B
Adjusted EBITDA (Financial Highlights)$1.355B$1.099B
Adjusted EBITDA margin (Segment results)24.1%20.8%
Adjusted free cash flow (Cash Flow reconciliation)$1.102B$781M

Underlying operations were good, especially in hospitals, but not uniformly volume-led. Hospital adjusted EBITDA rose to $818 million from $607 million, with admissions up 2.8% and adjusted admissions up 3.2%. Ambulatory revenue increased 7.5% and EBITDA rose 9.1%, but surgical cases fell 1.5%; most of the ambulatory revenue growth came from a 6.1% increase in revenue per case rather than more procedures. 〔0〕

The main quality caveat is the $147 million Q3 EBITDA lift from the Conifer transition. Tenet recognized a $97 million timing-related revenue adjustment and about $50 million of transition efficiencies as the CommonSpirit revenue-cycle-services handoff moved faster than previously scheduled. Management says this does not change full-year contract-termination or revenue expectations, but it does make Q3 reported profitability look stronger than the recurring run rate.

Guidance was raised on more than the one-time accounting item. Full-year adjusted EBITDA is now guided to $5.05 billion–$5.20 billion, and adjusted free cash flow to $2.825 billion–$3.125 billion, with the company pointing to sustained same-facility revenue growth and expense discipline. The raise is therefore a meaningful upgrade to the operating story, although payer mix and weaker procedure volumes remain visible offsets.

Bottom line: Tenet delivered a genuine earnings beat and raised its cash-generation outlook, strengthening the case that its margin and ambulatory strategy is working. The result is materially better than expected, but the Q3 headline is partly flattered by a $147 million transition-related benefit that will not repeat in the same form.

What to watch next

Q4 report and initial FY 2027 outlook

Original filing on SEC EDGAR

More Tenet Healthcare Corp news

Tenet earnings beat as EBITDA outlook jumps—but $147M was timing | THC Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.